Vaxxas launches research project to evaluate Nanopatch for polio vaccine delivery
The World Health Organization will provide funding to Vaxxas to support the project, specifically for pre-clinical studies and good manufacturing practices. Following the research, Nanopatches will enter the necessary clinical development and seek the regulatory approvals needed for distribution.
"The Nanopatch doesn't need to be kept refrigerated to maintain its efficacy - a tremendously important factor for the transportation and application of polio vaccine in the remote regions of the world where eradication efforts are most challenging," David Hoey, the CEO of Vaxxas, said. "The research we are undertaking with WHO's support aims to provide better vaccine solutions to reach all children anywhere with this life-saving health intervention."
Vaxxas is currently pursuing strategic plans to both license its technology to global pharmaceutical companies and advance vaccine candidates of its own. The company is collaborating with Merck & Co., Inc., to commercialize the Nanopatch for undisclosed vaccine candidates.
Vaxxas was founded in 2011 with $15 million of equity financing. The company expanded in 2012 by opening an office in Cambridge, Mass., to bring it closer to its global pharmaceutical partners and complement its research and development operations in Queensland, Australia.